Yasuhiko Yamano

Dr. Yasuhiko Yamano


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2024 in Arthritis & Rheumatology
Verified
Journal Article
Open access
SFSara Faghihi‐Kashani
Sara Faghihi‐Kashani
AYAkira Yoshida
Akira Yoshida
FBFrancisca Bozan
Francisca Bozan
Giovanni ZanframundoGiovanni Zanframundo
Giovanni Zanframundo
DRDavide Rozza
Davide Rozza
TIthe Classification Criteria for Anti‐Synthetase Syndrome Project participating investigators
the Classification Criteria for Anti‐Synthetase Syndrome Project participating investigators
Objective: Anti‐synthetase syndrome (ASSD) is a rare systemic autoimmune rheumatic disease (SARD) with significant heterogeneity and no shared classification criteria. We aimed to identify clinical and serological features associated with ASSD that may be suitable for inclusion in the data‐driven classification criteria for ASSD.Methods: We used a large, international, multicenter “Classification Criteria for Anti‐synthetase Syndrome” (CLASS) project database, which includes both patients with ASSD and controls with mimicking conditions, namely, SARDs and/or interstitial lung disease (ILD). The local diagnoses of ASSD and controls were confirmed by project team members. We employed univariable logistic regression and multivariable Ridge regression to evaluate clinical and serological features associated with an ASSD diagnosis in a randomly selected subset of the cohort.Results: Our analysis included 948 patients with ASSD and 1,077 controls. Joint, muscle, lung, skin, and cardiac involvement were more prevalent in patients with ASSD than in controls. Specific variables associated with ASSD included arthritis, diffuse myalgia, muscle weakness, muscle enzyme elevation, ILD, mechanic's hands, secondary pulmonary hypertension due to ILD, Raynaud phenomenon, and unexplained fever. In terms of serological variables, Jo‐1 and non–Jo‐1 anti‐synthetase autoantibodies, antinuclear antibodies with cytoplasmic pattern, and anti‐Ro52 autoantibodies were associated with ASSD. In contrast, isolated arthralgia, dysphagia, electromyography/magnetic resonance imaging/muscle biopsy findings suggestive of myopathy, inflammatory rashes, myocarditis, and pulmonary arterial hypertension did not differentiate between patients with ASSD and controls or were inversely associated with ASSD.Conclusion: We identified key clinical and serological variables associated with ASSD, which will help clinicians and offer insights into the development of data‐driven classification criteria for ASSD. image

15 March 2022 in Respirology
Verified
Journal Article
Closed access
RTReoto Takei
Reoto Takei
KBKevin K. Brown
Kevin K. Brown
YYYasuhiko Yamano
Yasuhiko Yamano
KKKensuke Kataoka
Kensuke Kataoka
TYToshiki Yokoyama
Toshiki Yokoyama
YKYasuhiro Kondoh
Yasuhiro Kondoh

16 July 2018 in Respirology
Verified
Journal Article
Closed access
PDF file
YYYasuhiko Yamano
Yasuhiko Yamano
HTHiroyuki Taniguchi
Hiroyuki Taniguchi
YKYasuhiro Kondoh
Yasuhiro Kondoh
MAMasahiko Ando
Masahiko Ando
KKKensuke Kataoka
Kensuke Kataoka
YHYoshinori Hasegawa
Yoshinori Hasegawa

25 March 2018 in Respirology
Verified
Journal Article
Closed access
PDF file
ASAtsushi Suzuki
Atsushi Suzuki
YKYasuhiro Kondoh
Yasuhiro Kondoh
JSJeffrey J. Swigris
Jeffrey J. Swigris
MAMasahiko Ando
Masahiko Ando
TKTomoki Kimura
Tomoki Kimura
YHYoshinori Hasegawa
Yoshinori Hasegawa

22 March 2023 in Viruses
Verified
Journal Article
Open access
PDF file
YMYoshikazu Mutoh
Yoshikazu Mutoh
TUTakumi Umemura
Takumi Umemura
TNTakeshi Nishikawa
Takeshi Nishikawa
KKKaho Kondo
Kaho Kondo
YNYuta Nishina
Yuta Nishina
YKYasuhiro Kondoh
Yasuhiro Kondoh
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for patients with the 2019 coronavirus (COVID-19). However, little is known about their effectiveness in older adults and those at high risk of disease progression. This retrospective single-center observational study assessed and compared the outcomes of COVID-19 treated with MOV and NMV/r in a real-world community setting. We included patients with confirmed COVID-19 combined with one or more risk factors for disease progression from June to October 2022. Of 283 patients, 79.9% received MOV and 20.1% NMV/r. The mean patient age was 71.7 years, 56.5% were men, and 71.7% had received ≥3 doses of vaccine. COVID-19-related hospitalization (2.8% and 3.5%, respectively; p = 0.978) or death (0.4% and 3.5%, respectively; p = 0.104) did not differ significantly between the MOV and NMV/r groups. The incidence of adverse events was 2.7% and 5.3%, and the incidence of treatment discontinuation was 2.7% and 5.3% in the MOV and NMV/r groups, respectively. The real-world effectiveness of MOV and NMV/r was similar among older adults and those at high risk of disease progression. The incidence of hospitalization or death was low.

24 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YZYoshiaki Zaizen
Yoshiaki Zaizen
YTYuri Tachibana
Yuri Tachibana
YKYukio Kashima
Yukio Kashima
Andrey BychkovAndrey Bychkov
Andrey Bychkov
KTKazuhiro Tabata
Kazuhiro Tabata
JFJunya Fukuoka
Junya Fukuoka
The pathogenesis of pleuroparenchymal fibroelastosis (PPFE), a rare interstitial lung disease, remains unclear. Based on previous reports and our experience, we hypothesized that alveolar epithelial denudation (AED) was involved in the pathogenesis of PPFE. This multicenter retrospective study investigated the percentage of AED and the features of the denudated areas in 26 PPFE cases, 30 idiopathic pulmonary fibrosis (IPF) cases, and 29 controls. PPFE patients had lower forced vital capacities and higher residual volume/total lung capacities in pulmonary function tests compared to IPF and control patients. Histopathologically, subpleural fibroelastosis was observed in PPFE, and AED was observed in 12.01% of cases in the subpleural or interlobular septa regardless of fibroelastosis. The percentage of AED in the PPFE group was significantly higher than that in the IPF group (6.84%; p = 0.03) and the normal group (1.19%; p < 0.001). In the IPF group, the percentage of AED and the presence of PPFE-like lesions in the upper lobes were examined radiologically, but no correlation was found. We showed that AED frequently occurred in PPFE. AED was less frequent in IPF, which, in combination with imaging data, suggests that PPFE may have a different pathogenesis from IPF.